Tirzepatide
GRABS-0
Eli Lilly · Phase 2/3 · Active, not recruiting · Enrollment 30
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Tirzepatide Group | n/r | n/r | n/r | n/r |
| Control - Standard of care Post-Gastric Bypass Surgery | n/r | n/r | n/r | n/r |
Not shown
- Tirzepatide Group: endpoint not reported
- Control - Standard of care Post-Gastric Bypass Surgery: endpoint not reported